← All trials
NCT05845840
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 15, 2023
- Primary completion
- Nov 23, 2023
- Completion date
- Apr 15, 2024
- First posted
- May 6, 2023
- Last posted
- Aug 18, 2023
- Enrollment
- 52
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Brii BiosciencesLead sponsor
- IDT Australia Ltd.Overall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.